FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced positive results from its pilot clinical study evaluating the safety and clinical utility of GEM OS1 Bone Graft for the treatment of distal radius (wrist) fractures. In the randomized, controlled study evaluating distal radius fractures treated with external fixation versus external fixation augmented with GEM OS1, patients treated with GEM OS1 demonstrated faster bone healing at the fracture site as measured by CT scans. Additionally, the product candidate proved to be safe, with no reported serious adverse events related to the device. This is the third anatomic site (the other two being the foot/ankle and the jaws) and the fourth human clinical trial in which the Company’s Growth-factor Enhanced Matrix (GEM®) technology has demonstrated the stimulation of bone regeneration.
